HomeAI · summaries
Storia in 4 fonti
Groundbreaking Pancreatic Cancer Drug Shows Promise in Lung Cancer
Response rates with daraxonrasib ranged from 31% to 37% in previously treated RAS-mutant NSCLC
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
nature.com
Landmark pancreatic cancer drug shows potential against lung cancer too
Results bolster hopes that the drug daraxonrasib could prove effective against a variety of tumours.
- ·
healio.com
Daraxonrasib exhibits ‘encouraging signal’ in RAS -mutant metastatic lung cancer
An oral drug widely expected to transform pancreatic cancer treatment has demonstrated encouraging clinical activity in metastatic non-small cell lung cancer. Daraxonrasib…
